Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease-Reference-Cited by-同舟云学术

Efficacy of Lifitegrast Ophthalmic Solution, 5.0%, in Patients With Moderate to Severe Dry Eye Disease

Published:2021-11-01 Issue:11 Volume:139 Page:1200
ISSN:2168-6165
Container-title:JAMA Ophthalmology
language:en
Short-container-title:JAMA Ophthalmol

Author:

Holland Edward J.¹,Jackson Mitchell A.²,Donnenfeld Eric³,Piccolo Rebecca⁴,Cohen Alisa⁴,Barabino Stefano⁵,Rolando Maurizio⁶,Figueiredo Francisco C.⁷

Affiliation:

1. Cincinnati Eye Institute, University of Cincinnati, Cincinnati, Ohio

2. Jacksoneye, Lake Villa, Illinois

3. New York University Medical Center, New York

4. Novartis Pharmaceuticals Corporation, East Hanover, New Jersey

5. Ocular Surface and Dry Eye Center, University of Milan, Milan, Italy

6. Ocular Surface Centre, ISPRE (Instituto di Medicina Oftalmica) Ophthalmic, Genoa, Italy

7. Department of Ophthalmology, Royal Victoria Infirmary and Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle, United Kingdom

Publisher

American Medical Association (AMA)

Subject

Ophthalmology

Link

https://jamanetwork.com/journals/jamaophthalmology/articlepdf/2784639/jamaophthalmology_holland_2021_oi_210058_1636144586.97418.pdf

Reference39 articles.

1. TFOS DEWS II definition and classification report.;Craig;Ocul Surf,2017

2. TFOS DEWS II epidemiology report.;Stapleton;Ocul Surf,2017

3. TFOS DEWS II pathophysiology report.;Bron;Ocul Surf,2017

4. Molecular evidence for the role of inflammation in dry eye disease.;Ganesalingam;Clin Exp Optom,2019

5. Lifitegrast: a novel drug for treatment of dry eye disease.;Abidi;J Pharmacol Pharmacother,2016

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An LC-MS/MS method for the determination of Lifitegrast in human plasma and tear and its application in the pharmacokinetic study;Bioanalysis;2024-06-02

2. Long-Term Safety and Efficacy of a Water-Free Cyclosporine 0.1% Ophthalmic Solution for Treatment of Dry Eye Disease: ESSENCE-2 OLE;Cornea;2024-05-21

3. Therapeutic Targets in the Management of Dry Eye Disease Associated with Sjögren’s Syndrome: An Updated Review of Current Insights and Future Perspectives;Journal of Clinical Medicine;2024-03-20

4. Establishment of an LC-MS/MS method for quantification of lifitegrast in rabbit plasma and ocular tissues and its application to pharmacokinetic study;Journal of Chromatography B;2023-09

5. Ocular graft-versus-host disease (oGVHD): From A to Z;Survey of Ophthalmology;2023-07